摘要:
Compounds of formula (I) in which M, B1, B2, R1, R2, R6, R7, K1 and K2 have the meanings indicated in the description are novel active tryptase inhibitors.
摘要:
The invention relates to the combined administration of a pulmonary surfactant and a PDE2 inhibitor for the treatment of a disease in which pulmonary surfactant malfunction and/or phosphodiesterase 2 (PDE2) activity is detrimental.
摘要:
The invention relates to the combined administration of PDE4 or PDE3/4 inhibitors and histamine receptor antagonists for the treatment of respiratory diseases.
摘要:
Compounds of the formula I, wherein M, A1, A2, K1 and K2 have the meanings as indicated below are tryptase inhibitors. M is a central building block containing an acetylene containing linking group. A1 and A2 are carbonyl containing linking groups K1 is -B3-X1, -B3-Y1 or B3-Z1-B5-X1, K2 is -B4-X2, -B4-Y2 or -B4-Z2-B6-X2, B3 and B4 are identical or different and are a bond or 1-4C-alkylene, B5 and B6 are identical or different and are a bond or 1-2C-alkylene, X1 and X2 are identical or different and are amino, aminocarbonyl or amidino, Y1 and Y2 are imidazol -1-yl, Z1 and Z2 are identical or different and are 5,2-pyridinylene, 6-methyl-5,2-pyridinylene, 4,1-piperidinylene, 3,6-indazolylene, 3,6-indolylene, 1,3-phenylene, 1,4-phenylene, 1,3,-cyclohexalene or 1,4-cyclohexylene, the salts of these compounds, and the N-oxides of the nitrogen-containing heteroalryls, heteroarylenes and heterocycloalkylenes, and their salts, where all those compounds are excluded in which, owing to the meaning of the variables, there would be a direct linkage of two hereroatoms or two carbonyl groups.
摘要:
Compounds of formula (I) in which M, B1, B2, R1, R2, R6, R7, K1 and K2 have the meanings indicated in the description are novel active tryptase inhibitors.
摘要:
The invention relates to the administration of roflumilast oral or untravenously and an anticholinergic agent selected from the group of an ipratropium, oxitropium or tiotropium salt for the treatment of respiratory diseases.